Scientists find worrying links between fatty liver disease and cancer — what the evidence shows and what it means
🩺 Scientists Find Link Between Fatty Liver Disease and Cancer — What You Should Know
A growing number of studies are uncovering a worrying connection between fatty liver disease and several types of cancer — not just liver cancer. Once thought of mainly as a liver problem linked to alcohol or obesity, new research shows that fatty liver disease may increase the risk of cancers in other parts of the body too.
So what exactly is happening — and what can you do to protect yourself?
What Is Fatty Liver Disease?
Fatty liver disease happens when too much fat builds up in the liver. When this occurs in people who drink little or no alcohol, it’s called nonalcoholic fatty liver disease (NAFLD) — or, more recently, metabolic dysfunction–associated steatotic liver disease (MASLD).
This condition is now incredibly common: about 1 in 4 people worldwide are affected. It’s often linked with obesity, type 2 diabetes, high blood pressure, and high cholesterol.
In many people, fatty liver causes no symptoms at first. But over time, it can lead to inflammation (NASH), fibrosis (scarring), cirrhosis, and in severe cases, liver cancer.
What Did Scientists Discover?
Researchers have long known that advanced fatty liver disease can lead to liver cancer (hepatocellular carcinoma). But recent large studies have shown something new:
people with fatty liver disease also have higher risks of other cancers, including:
-
Colorectal (bowel) cancer
-
Pancreatic cancer
-
Breast cancer
-
Lung cancer
-
Gynecologic cancers (such as uterine or ovarian)
A 2023 review found that people with NAFLD were more likely to develop colorectal cancer and precancerous colon polyps, even after accounting for obesity and diabetes.
Another major study linked NAFLD to a 30% higher risk of lung cancer.
Scientists warn that as fatty liver becomes more common, cancer rates related to it may also rise sharply.
How Can Fatty Liver Cause Cancer?
Researchers believe several biological processes connect fatty liver disease to tumor growth:
-
Chronic inflammation – Fat buildup in the liver causes inflammation and oxidative stress, which can damage DNA and trigger mutations.
-
Insulin resistance – Common in NAFLD, this leads to high insulin and growth-factor levels, which promote tumor cell growth.
-
Immune changes – Fatty liver can weaken the immune system’s ability to detect and destroy cancer cells.
-
Gut-liver link – An unhealthy gut microbiome may release toxins and metabolites that fuel inflammation in the liver and beyond.
All of these effects can spread beyond the liver, potentially encouraging cancer in other organs.
What Does This Mean for You?
It’s important to remember: having fatty liver disease doesn’t mean you’ll get cancer.
But it does mean your body may be in an inflammatory, high-risk state — one that deserves attention.
Here’s what doctors recommend:
1. Get tested if you’re at risk
If you’re overweight, have diabetes, or high cholesterol, ask your doctor about a liver ultrasound or blood tests to check for fatty liver.
Early diagnosis can prevent long-term damage.
2. Adopt a liver-friendly lifestyle
Lifestyle changes can actually reverse early fatty liver:
-
Lose weight gradually – Even a 7–10% weight loss can reduce liver fat.
-
Eat a balanced diet – Go for a Mediterranean-style diet rich in fruits, vegetables, whole grains, and olive oil.
-
Limit sugar and processed foods.
-
Exercise regularly – Aim for 150 minutes of activity per week.
3. Stay up to date on cancer screenings
People with NAFLD should not skip routine screenings for colorectal, breast, and cervical cancers.
If you have advanced liver scarring or cirrhosis, you may need liver ultrasound screenings every six months to detect cancer early.
4. Control your metabolic health
Managing diabetes, blood pressure, and cholesterol lowers both liver and cancer risk.
Quitting smoking and limiting alcohol also make a major difference.
Why This Matters Now
Fatty liver disease is becoming one of the leading causes of liver cancer, especially as hepatitis infections decline.
Experts say that cancer-related deaths among people with NAFLD — including cancers outside the liver — are rising faster than expected.
The good news? Fatty liver disease is largely preventable and reversible through lifestyle changes and medical management.
By acting early, you can protect your liver and lower your long-term cancer risk.
The Bottom Line
Scientific evidence increasingly shows that fatty liver disease isn’t just a liver issue — it’s a whole-body condition that may raise your risk for several cancers.
Understanding and treating it early can make a huge difference.
Your liver health is your life health.
Take action today — eat well, stay active, get checked — and protect yourself for the long run.
A growing body of research has strengthened scientific evidence that fatty liver disease — once thought of primarily as a liver problem tied to alcohol or obesity — is associated not only with liver cancer but also with higher risks of several extra-hepatic cancers. Over the past decade investigators around the world have moved from describing correlations to probing biological mechanisms that could explain how fatty liver creates a permissive environment for cancer. The findings have large public-health implications because fatty liver is hugely common and rising in prevalence worldwide.
This article summarizes the current evidence, explains plausible biological pathways, discusses which cancers appear most strongly linked, outlines the limitations of existing studies, and describes what clinicians and patients might reasonably consider now — from prevention to surveillance. Where possible, I cite recent large studies and reviews so you can follow the primary sources. (PMC)
What is fatty liver disease (NAFLD / MASLD) — and how common is it?
“Fatty liver disease” is a broad term describing accumulation of fat (steatosis) in liver cells. Nonalcoholic fatty liver disease (NAFLD) — recently reclassified by some experts as metabolic dysfunction-associated steatotic liver disease (MASLD) — occurs when fat builds up in the liver in people who drink little or no alcohol, usually in association with metabolic risk factors such as obesity, type 2 diabetes, high blood pressure, and dyslipidemia. NAFLD spans a spectrum from simple steatosis (fat only) to nonalcoholic steatohepatitis (NASH, fat with inflammation) and ultimately to fibrosis, cirrhosis and liver failure in a subset of patients. (PMC)
The public-health scale is striking: systematic reviews estimate that roughly one in four people worldwide has NAFLD, and incidence continues rising in many countries—particularly among younger adults and men—driven by obesity, sedentary lifestyles, and diabetes. As NAFLD prevalence increases, so does the absolute number of people at risk of long-term liver complications and, potentially, cancer. (PMC)
Which cancers are linked to fatty liver disease?
1. Hepatocellular carcinoma (HCC) — the liver cancer link is well established
The clearest and most direct association is between NAFLD and hepatocellular carcinoma (HCC), the commonest form of primary liver cancer. Patients with advanced NAFLD (NASH with fibrosis or cirrhosis) have a substantially higher risk of developing HCC than people without fatty liver. In some countries NAFLD is becoming one of the leading causes of HCC as viral hepatitis becomes better controlled. Importantly, HCC can sometimes develop in NAFLD patients even without cirrhosis, which complicates standard surveillance strategies that focus on people with cirrhosis. (The Lancet)
2. Extrahepatic cancers — evidence for colorectal, pancreatic, lung, breast and others
Beyond liver cancer, a number of large observational studies and meta-analyses have reported higher rates of several extrahepatic cancers among people with NAFLD. Meta-analyses and cohort studies suggest associations — sometimes modest, sometimes more pronounced — for colorectal cancer (including higher rates of colorectal adenomas and early-onset colorectal cancer), pancreatic cancer, lung cancer, breast cancer, and certain gynecologic cancers. The size of the associations varies by study and cancer type, and many analyses try (with variable success) to adjust for shared risk factors such as obesity, smoking, and diabetes, which themselves raise cancer risk. (PMC)
A 2023 meta-analysis and subsequent cohort analyses also signaled an increased risk of colorectal cancer and colorectal adenomas in patients with NAFLD, while other observational work linked NAFLD with higher risks of lung and other non-digestive cancers. Large recent reviews highlight that deaths from extrahepatic cancers among NAFLD patients may far outnumber deaths from HCC, underscoring the broader oncologic burden associated with metabolic liver disease. (PMC)
How might fatty liver disease promote cancer? (plausible biological mechanisms)
The observational associations are not proof of causation, but several plausible biological pathways could connect NAFLD to tumor development and progression:
-
Chronic inflammation and oxidative stress. Steatohepatitis (fat with inflammation) generates inflammatory cytokines, reactive oxygen species and DNA damage that can promote oncogenic mutations in liver cells — a well-recognized path to HCC. Systemic inflammation associated with metabolic dysfunction could also affect distant tissues and promote tumorigenesis. (PMC)
-
Fibrosis and altered tissue microenvironment. Fibrotic remodeling in the liver (and possibly systemic changes in connective tissue biology) can create a microenvironment favorable to malignant transformation and reduce normal immune surveillance. Even early fibrotic changes may alter local signaling in ways that support cancer cell survival. (The Lancet)
-
Metabolic dysregulation and insulin resistance. Hyperinsulinemia and elevated levels of insulin-like growth factors — common in NAFLD and obesity — provide proliferative and anti-apoptotic signals that can promote tumor growth in multiple tissues. Lipid alterations can also change cellular membranes and signaling pathways relevant to cancer biology. (PMC)
-
Immune dysfunction and tumor surveillance. NAFLD is associated with changes in both innate and adaptive immunity; impaired anti-tumor immune responses may permit early tumors to survive and grow. Recent laboratory work has shown, for example, that fatty liver alters immune cells in ways that help metastatic colorectal cancer cells take root in the liver. (Cancer.gov)
-
Microbiome and gut-liver axis. Alterations of the gut microbiome and increased gut permeability (common in metabolic disease) can deliver bacterial products and metabolites to the liver, fueling inflammation and potentially creating systemic pro-tumor environments. (PMC)
Taken together, these mechanisms form a biologically plausible network through which fatty liver may contribute—directly or indirectly—to cancer risk. But disentangling direct causal effects from shared risk factors (like obesity and diabetes) remains challenging.
What do the large studies say — key findings
Below are high-level summaries — each has caveats but together they show a consistent pattern.
-
NAFLD substantially raises HCC risk. Multiple cohort studies, systematic reviews and clinical registries show that NAFLD, especially when fibrosis/cirrhosis is present, is associated with higher HCC incidence and mortality. Some evidence indicates even non-cirrhotic NAFLD can lead to HCC in a minority of patients, which complicates surveillance strategies that rely on cirrhosis as the trigger for screening. (The Lancet)
-
Extrahepatic cancer risk is increased in many analyses. Meta-analyses pooling hundreds of thousands of patients report modest but significant increases in risk for colorectal cancer, lung cancer and other malignancies among people with NAFLD, after statistical adjustment for common confounders in many—but not all—studies. One meta-analysis found a roughly 30% increased lung cancer risk associated with NAFLD, for example, though results vary by population and how NAFLD was defined. (PMC)
-
Younger onset of NAFLD may raise lifetime cancer risk. Some cohort data suggest that early-onset NAFLD (diagnosed at younger ages) may be associated with especially elevated risks of subsequent cancers, indicating the importance of preventing metabolic disease early in life. (JAMA Network)
-
Mortality from cancer is an important component of NAFLD burden. Large population studies indicate that in NAFLD cohorts, deaths attributable to extrahepatic cancers can exceed deaths from HCC and liver failure, emphasizing that the clinical impact of NAFLD extends beyond the liver. (ecancer)
Important caveats and limitations
While the accumulated data are concerning and biologically plausible, it’s critical to understand what the evidence does and does not prove:
-
Predominance of observational data. Most evidence comes from observational cohorts and meta-analyses. These can identify associations but cannot definitively prove that NAFLD causes cancer — confounding factors (notably obesity, diabetes, alcohol, smoking and socioeconomic variables) complicate causal inferences. Researchers try to adjust for these, but residual confounding is hard to eliminate entirely. (PMC)
-
Heterogeneity in NAFLD definitions and detection. Studies vary in how they define and detect fatty liver — imaging, blood biomarkers, diagnostic codes, or biopsy — which affects comparability. Biopsy-proven NASH cohorts provide the clearest biological signal but are smaller and less representative. (PMC)
-
Variation by population and risk factor profiles. The magnitude of associations differs across age groups, sexes, ethnicities and countries; some signals are stronger in populations with high diabetes or obesity prevalence.
-
Potential reverse causation in some settings. In studies where cancer diagnosis and metabolic disease are close in time, there’s a risk that preclinical cancer or its treatments influence metabolic status, producing spurious associations.
Because of these limitations, leading reviews call for cautious interpretation, further prospective studies, and mechanistic research to test causality. (PMC)
Clinical and public-health implications
Although uncertainty remains about the precise size of cancer risk directly caused by NAFLD, the following practical implications are reasonable:
Prevention is primary
Preventing and reversing fatty liver through lifestyle interventions (weight loss, increased physical activity, healthy diet, glycemic control) reduces the metabolic drivers that plausibly contribute to both liver disease and extrahepatic cancer. Dietary patterns shown to reduce metabolic risk and HCC risk (for example, Mediterranean-style diets, increased fiber and omega-3 intake) are sensible public-health strategies. Recent nutrition studies indicate diet can substantially influence HCC risk, particularly among people with metabolic risk factors. (EatingWell)
Targeted screening and surveillance
-
For HCC, current guidelines prioritize surveillance for people with cirrhosis; however, the observation that HCC can occur in non-cirrhotic NAFLD has prompted debate about whether surveillance strategies should be broadened for high-risk non-cirrhotic NAFLD patients (for example older patients with diabetes and advanced fibrosis). Any expansion must balance potential benefits against costs and false positives. (The Lancet)
-
For extrahepatic cancers, the data do not yet support broad new screening programs solely because someone has NAFLD. However, clinicians should ensure patients with NAFLD receive guideline-recommended age- and risk-based cancer screenings (e.g., colorectal screening), and should consider metabolic control and smoking cessation as part of cancer prevention. (JAMA Network)
Research and drug development
There is active research into pharmacological therapies for NASH and fibrosis; if these drugs can reduce inflammation and fibrosis, they may in principle reduce HCC risk. Long-term trials and real-world studies are needed to evaluate whether treating NASH lowers eventual cancer incidence. (PMC)
What should patients with fatty liver know and do?
-
Don’t panic — take action. Having fatty liver is common and in many people it does not progress. But it is a sign that metabolic health needs attention. Lifestyle measures that improve weight, diet quality, and physical activity are the first-line therapy and can reduce liver fat and inflammation.
-
Work with your clinician on risk estimation. Ask about the severity of liver disease (noninvasive fibrosis testing is widely available) and whether you need more intensive monitoring. If you have advanced fibrosis or cirrhosis, follow HCC surveillance recommendations. (The Lancet)
-
Keep up age-appropriate cancer screening. Ensure you receive standard screenings (e.g., colorectal, breast, cervical) at the recommended intervals — people with metabolic disease should be especially attentive to screening reminders. (JAMA Network)
-
Address modifiable risk factors. Manage diabetes, lose excess weight when safe and appropriate, adopt a balanced diet rich in whole foods and fiber, cut down on alcohol, and stop smoking. These steps reduce both liver complications and general cancer risk. (EatingWell)
Where the research needs to go next
To move from association to actionable cause-and-effect knowledge, researchers need:
-
Large, prospective cohorts with standardized NAFLD definitions and long follow-up to measure site-specific cancer incidence while controlling for confounders.
-
Mendelian randomization and other genetic-epidemiology approaches to test for causal links.
-
Mechanistic studies in humans and animal models to show how fatty liver biology directly promotes tumor initiation or progression.
-
Clinical trials that evaluate whether treating hepatic inflammation and fibrosis reduces long-term cancer outcomes.
-
Disaggregated analyses across age, sex, race/ethnicity and metabolic subgroups to identify who is at highest risk and might benefit most from targeted interventions. (PMC)
Bottom line
A substantial and growing literature links fatty liver disease to increased risk of hepatocellular carcinoma and suggests elevated risks for various extrahepatic cancers as well. The links are biologically plausible — chronic inflammation, fibrosis, insulin resistance, immune changes and gut-liver interactions all provide mechanisms that could promote malignancy. However, most evidence is observational, and separating direct causal effects of fatty liver from the shared influences of obesity and diabetes remains challenging.
For patients and clinicians, the practical response today is clear: prioritize prevention (weight, diet, physical activity, diabetes control), ensure guideline-recommended screenings, identify people with advanced fibrosis who need HCC surveillance, and support further research. Because NAFLD affects such a large proportion of the population, even modest increases in cancer risk would translate into a major public-health burden — making prevention and early intervention urgent priorities. (PMC)
Selected sources and further reading
-
Thomas JA, et al. Hepatocellular and extrahepatic cancer risk in people with NAFLD (review). Lancet Gastroenterology & Hepatology, 2024. (The Lancet)
-
Liu C., et al. New-Onset Age of Nonalcoholic Fatty Liver Disease and Risk of Cancer. JAMA Network Open, 2023. (JAMA Network)
-
Cancer Currents (NIH/NCI): How Fatty Liver Disease Helps Cancer Thrive in the Liver (2023). (Cancer.gov)
-
Muhamad NA, et al. The Global Prevalence of NAFLD (systematic review). PMC, 2023. (PMC)
-
Wang W., et al. The Effect of Nonalcoholic Fatty Liver Disease on Cancer Risk (review), 2025. (PMC)
